beta

NGNE

Neurogene Inc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

neoleukin therapeutics, inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. the company's lead product candidate is nl-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (il)-2/il-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. the company was formerly known as aquinox pharmaceuticals, inc. and changed its name to neoleukin therapeutics, inc. in august 2019. neoleukin therapeutics, inc. was founded in 2003 and is headquartered in seattle, washington.

Market Cap: 357 Million

Primary Exchange: NASDAQ

Website: neoleukin.com

Shares Outstanding: 9.4 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 0.39659795190424696

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 20 trading days

From: 2024-02-06 To: 2024-02-26

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud